Sponsor or institution

Clinical trials and research at BeOne Medicines

• 40Clinical trials
• 35Countries

Newest trials

All recruiting trials (40)

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• BGB-43395 drug interaction study in healthy adults

  This study tests if the drug BGB-43395 changes how other medicines are processed in healthy adults.

  Recruiting Phase 1 BeOne Medicines · Dallas, Texas · NCT07820891

• BG-85738 alone or with other anticancer drugs in RAS-mutant advanced or metastatic solid tumors

  This study tests BG-85738, alone or with other cancer drugs, in adults whose solid tumors have RAS mutations and have progressed.

  Recruiting at 3 sites Phase 1 BeOne Medicines · South Brisbane, Queensland and 2 other locations · NCT07746141

• Tislelizumab with chemotherapy in first-line advanced ESCC in Japanese patients

  This study tests whether giving tislelizumab every 2 weeks or every 4 weeks with standard chemotherapy can safely and effectively treat Japanese patients with newly diagnosed, unresectable or metastatic esophageal squamous cell carcinoma.

  Recruiting at 4 sites Phase 2 BeOne Medicines · Yokohama, Kanagawa and 3 other locations · NCT07733180

• Understanding how two tablet formats and food affect BGB-58067 in healthy adults

  This study tests whether two tablet formulations of BGB-58067 behave similarly in the blood and how meals change its absorption in healthy adults.

  Recruiting Phase 1 BeOne Medicines · Adelaide, South Australia · NCT07712640

• Tislelizumab use in European patients with NSCLC or ES-SCLC in routine care

  This study looks at how tislelizumab is used in real-world European patients with advanced NSCLC or extensive-stage SCLC and what outcomes are seen in everyday clinical practice.

  Recruiting at 6 sites BeOne Medicines · Córdoba and 5 other locations · NCT07652736

• BG-75202 alone or with other drugs in myeloid malignancies

  This study tests BG-75202, a KAT6A/B inhibitor, alone and with other agents to see if it is safe and potentially helpful for adults with myeloid malignancies.

  Recruiting at 17 sites Phase 1 BeOne Medicines · Concord, New South Wales and 16 other locations · NCT07619287

• How the drug BGB-58067 behaves when taken with phenytoin or itraconazole

  This study tests how BGB-58067 is processed in healthy volunteers when taken with a CYP3A inducer (phenytoin) or a CYP3A inhibitor (itraconazole).

  Recruiting Phase 1 BeOne Medicines · Adelaide, South Australia · NCT07590102

• Tislelizumab plus chemotherapy for advanced gastric, gastroesophageal, and esophageal squamous cancers in U.S. racial and ethnic minority patients

  This will test whether adding tislelizumab to standard chemotherapy helps U.S. racial and ethnic minority patients with HER2-negative, PD-L1-positive unresectable or metastatic gastric, gastroesophageal, or esophageal squamous cell cancer.

  Recruiting at 9 sites Phase 2 BeOne Medicines · Bullhead City, Arizona and 8 other locations · NCT07554521

• BGB-43395 plus letrozole vs standard CDK4/6 inhibitor with letrozole for advanced HR+/HER2- breast cancer

  A phase 3 trial tests whether adding BGB-43395 to letrozole works better than the usual CDK4/6 inhibitor plus letrozole in adults with advanced or metastatic HR+/HER2- breast cancer who have not yet received treatment for advanced disease.

  Recruiting at 241 sites Phase 3 BeOne Medicines · Birmingham, Alabama and 240 other locations · NCT07492641

• BG-C0979 (alone or with tislelizumab) for adults with advanced solid tumors

  This trial will try the antibody-drug conjugate BG-C0979, alone or combined with tislelizumab, in adults with advanced solid tumors to see if it is safe, how it acts in the body, and whether it shows early signs of shrinking tumors.

  Recruiting at 18 sites Phase 1 BeOne Medicines · Boston, Massachusetts and 17 other locations · NCT07414836

• Safety of BG-A3004 in healthy volunteers and people with immune-mediated skin diseases

  This study will test whether single and multiple doses of the experimental drug BG-A3004 are safe and how the body handles it in healthy adults and people with immune-mediated skin diseases.

  Recruiting at 11 sites Phase 1 BeOne Medicines · Beijing, Beijing Municipality and 10 other locations · NCT07412691

• Sonrotoclax plus zanubrutinib versus venetoclax plus acalabrutinib for adults with untreated CLL

  This tests whether a fixed-duration combination of sonrotoclax plus zanubrutinib works as well as or better than venetoclax plus acalabrutinib for adults with previously untreated CLL who need treatment.

  Recruiting at 114 sites Phase 3 BeOne Medicines · Duarte, California and 114 other locations · NCT07277231

• Testing BG-75098 alone and with other drugs in adults with advanced solid tumors

  This will test whether BG-75098, alone or combined with BGB-43395 or fulvestrant, is safe and shows activity in adults with advanced solid tumors who have had prior standard treatments.

  Recruiting at 23 sites Phase 1 BeOne Medicines · Birmingham, Alabama and 22 other locations · NCT07226349

• BG-75202 alone and with other therapies for adults with advanced breast cancer and other solid tumors

  This trial will test whether BG-75202, a KAT6A/B inhibitor given alone or with other cancer drugs, is safe and can help adults with advanced breast cancer or other solid tumors.

  Recruiting at 32 sites Phase 1 BeOne Medicines · Birmingham, Alabama and 31 other locations · NCT07222267

• BG-C0902 alone and with other therapies for people with advanced solid tumors

  This study will test whether BG-C0902, given alone or with other cancer drugs, is safe and can shrink tumors in people with advanced solid tumors.

  Recruiting at 15 sites Phase 1 BeOne Medicines · Houston, Texas and 14 other locations · NCT07181681

• Subcutaneous versus intravenous tislelizumab with chemotherapy for unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

  This will test whether giving tislelizumab as a subcutaneous injection instead of an IV infusion, both with chemotherapy, works well and is safe as first treatment for adults with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

  Recruiting at 88 sites Phase 3 BeOne Medicines · Chandler, Arizona and 94 other locations · NCT07043400

• Tacabrutideg (BGB-16673) for Chronic Spontaneous Urticaria: Safety and PK in Adults and Healthy Volunteers

  This Phase 1b study tests whether multiple doses of tacabrutideg are safe and well tolerated in adults with CSU and in healthy people.

  Recruiting Phase 1 BeOne Medicines · Beijing, Beijing Municipality and 8 other locations · NCT07005713

• Comparing a BTK-targeted protein degrader (BGB-16673) with pirtobrutinib for adults with relapsed or refractory CLL or SLL

  This trial tests whether BGB-16673 works better and is as safe as pirtobrutinib for adults whose CLL or SLL has come back or not responded after prior covalent BTK inhibitor treatment.

  Recruiting at 217 sites Phase 3 BeOne Medicines · Birmingham, Alabama and 216 other locations · NCT06973187

• Comparing sonrotoclax combinations versus venetoclax plus rituximab for relapsed or refractory CLL/SLL

  This trial will test whether sonrotoclax combined with obinutuzumab or with rituximab works better than venetoclax plus rituximab for adults whose CLL/SLL has come back or not responded to prior treatment.

  Recruiting at 181 sites Phase 3 BeOne Medicines · Laguna Hills, California and 194 other locations · NCT06943872

• Comparing BGB-16673 to standard treatments for chronic lymphocytic leukemia

  This study is testing a new treatment called BGB-16673 to see if it works better than standard options for people with chronic lymphocytic leukemia who have already tried other therapies.

  Recruiting at 132 sites Phase 3 BeOne Medicines · Jonesboro, Arkansas and 131 other locations · NCT06846671

• Treatment of advanced or metastatic solid tumors with BGB-B455

  This study is testing a new treatment called BGB-B455 to see if it can help adults with advanced or metastatic solid tumors feel better and improve their condition.

  Recruiting at 10 sites Phase 1 BeOne Medicines · Celebration, Florida and 10 other locations · NCT06803680

• Testing a new combination of drugs for advanced breast cancer

  This study is testing a new combination of drugs to see if they can help adults with advanced breast cancer that hasn't responded to previous treatments.

  Recruiting at 13 sites Phase 1 BeOne Medicines · Iowa City, Iowa and 13 other locations · NCT06756932

• Comparing sonrotoclax plus zanubrutinib to placebo plus zanubrutinib for relapsed mantle cell lymphoma

  This study is testing if adding sonrotoclax to zanubrutinib can help adults with relapsed mantle cell lymphoma feel better compared to just taking zanubrutinib with a placebo.

  Recruiting at 95 sites Phase 3 BeOne Medicines · Birmingham, Alabama and 144 other locations · NCT06742996

• Investigating a new dosing schedule for sonrotoclax in blood cancer treatment

  This study is testing new ways to give the drug sonrotoclax to see if it can safely help people with chronic lymphocytic leukemia (CLL) feel better.

  Recruiting at 22 sites Phase 1/2 BeOne Medicines · Tampa, Florida and 21 other locations · NCT06697184

• Investigating a new cancer treatment for relapsed or refractory B-cell malignancies

  This study is testing a new cancer drug called BGB-16673 combined with other treatments to see if it can help people with tough-to-treat B-cell cancers feel better.

  Recruiting at 49 sites Phase 1/2 BeOne Medicines · Phoenix, Arizona and 48 other locations · NCT06634589

• Testing BG-C137 for advanced solid tumors

  This study is testing a new drug called BG-C137 to see if it can help people with advanced solid tumors who have run out of other treatment options.

  Recruiting at 51 sites Phase 1 BeOne Medicines · Los Angeles, California and 51 other locations · NCT06625593

• BG-T187 alone and with other cancer medicines for adults with advanced solid tumors

  This trial will test whether BG-T187, given alone and together with other cancer drugs, is safe and shows early anti-tumor activity in adults with advanced solid tumors who have already had prior treatment.

  Recruiting at 34 sites Phase 1 BeOne Medicines · Hackensack, New Jersey and 33 other locations · NCT06598800

• Evaluating BG-C477 for advanced solid tumors

  This study is testing a new drug called BG-C477 to see if it can safely help people with advanced solid tumors feel better and fight their cancer, both on its own and with other treatments.

  Recruiting at 59 sites Phase 1 BeOne Medicines · Goodyear, Arizona and 58 other locations · NCT06596473

• Testing BGB-58067 for advanced solid tumors with MTAP deficiency

  This study is testing a new drug called BGB-58067 to see if it can help people with advanced solid tumors that have a specific genetic deficiency when other treatments haven't worked.

  Recruiting at 101 sites Phase 1 BeOne Medicines · Los Alamitos, California and 100 other locations · NCT06589596

• Testing BGB-B2033 alone or with Tislelizumab for advanced solid tumors

  This study is testing a new treatment called BGB-B2033, alone or with another drug, to see if it can help people with advanced solid tumors feel better.

  Recruiting at 50 sites Phase 1/2 BeOne Medicines · Birmingham, Alabama and 50 other locations · NCT06427941

• Testing BG-C9074 and Tislelizumab in Patients with Advanced Solid Tumors

  This study is testing a new treatment called BG-C9074, alone and with another drug called Tislelizumab, to see if it can help people with advanced solid tumors feel better.

  Recruiting at 33 sites Phase 1 BeOne Medicines · Los Angeles, California and 36 other locations · NCT06233942

• BGB-43395 treatment for advanced breast cancer and other solid tumors

  This study is testing a new treatment called BGB-43395 for people with advanced breast cancer and other solid tumors to see if it works better alone or with other medications.

  Recruiting at 57 sites Phase 1 BeOne Medicines · Denver, Colorado and 60 other locations · NCT06120283

• Investigating BGB-26808 alone or with Tislelizumab for advanced solid tumors

  This study is testing a new treatment called BGB-26808, both by itself and with another drug called Tislelizumab, to see how well it works and what the best dose is for people with advanced solid tumors.

  Recruiting at 21 sites Phase 1 BeOne Medicines · Duarte, California and 27 other locations · NCT05981703

• Evaluating zanubrutinib for treating Waldenström Macroglobulinemia

  This study is testing how well zanubrutinib works and how safe it is for people with Waldenström macroglobulinemia, especially those with certain genetic traits and from different backgrounds.

  Recruiting at 6 sites BeOne Medicines · Huntsville, Alabama and 7 other locations · NCT05640102

• Treatment for B-cell malignancies using BGB-16673

  This study is testing a new drug called BGB-16673 to see if it can safely help people with different types of B-cell cancers.

  Recruiting at 29 sites Phase 1/2 BeOne Medicines · Bengbu, Anhui and 28 other locations · NCT05294731

• Exploring BGB-16673 for treating B-cell malignancies

  This study is testing a new drug called BGB-16673 to see if it can safely help people with certain types of B-cell cancers, like Marginal Zone Lymphoma and Follicular Lymphoma, who haven't had success with other treatments.

  Recruiting at 104 sites Phase 1/2 BeOne Medicines · Birmingham, Alabama and 113 other locations · NCT05006716

• Testing sonrotoclax alone and with other treatments for multiple myeloma

  This study is testing a new treatment called sonrotoclax, alone and with other medications, to see if it helps people with a specific type of multiple myeloma that has come back or hasn’t responded to other treatments.

  Recruiting at 64 sites Phase 1/2 BeOne Medicines · Birmingham, Alabama and 73 other locations · NCT04973605

• Evaluating BGB-11417 for treating myeloid malignancies

  This study is testing a new drug called BGB-11417, alone and with another medication, to see if it can safely help people with acute myeloid leukemia and myelodysplastic syndromes.

  Recruiting at 42 sites Phase 1/2 BeOne Medicines · Duarte, California and 46 other locations · NCT04771130

• Treatment of advanced solid tumors with Tislelizumab

  This study is testing if Tislelizumab can help people with advanced solid tumors that are hard to treat due to certain genetic features feel better and improve their health after other treatments have failed.

  Recruiting at 6 sites Phase 2 BeOne Medicines · Hefei, Anhui and 28 other locations · NCT03736889

Quick answers

How many clinical trials run by BeOne Medicines are recruiting right now?

40, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 35 countries. The most sites are in China (30 trials), Australia (29 trials), United States (29 trials), South Korea (16 trials), Brazil (15 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 20, Phase 3: 8, Phase 1/2: 7, Phase 2: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →